BioWorld

Categories

• Accelerated approval (2)
• acquisition (1)
• acute kidney injury (1)
• aging (1)
• AIDS (1)
• antibiotics (2)
• Antibody (2)
• Autism (1)
• Big pharma (28)
• bioethics (4)
• Biologic (8)
• Biosimilar (10)
• Biotech conferences (9)
• Biotechnology (95)
• Biotechnology Industry Organization (8)
• BLA (3)
• Cancer (16)
• Cardiovascular (2)
• China (4)
• chronic fatigue syndrome (3)
• Clinic (4)
• Clinical Trial (14)
• Collaboration (5)
• Complete Response Letter (4)
• Congress (2)
• Deals (6)
• Diabetes (1)
• DNA (2)
• Drug Approval (13)
• drug importation (1)
• embryonic stem cell research (1)
• emerging markets (2)
• epilepsy (1)
• ethics (1)
• European Medicines Agency (5)
• evolution (1)
• executive salaries (1)
• FDA (23)
• Financing (24)
• FOB (1)
• Follow-on biologic (2)
• FTC (1)
• Gene Therapy (5)
• generic (2)
• genetics (4)
• Genomics (7)
• Healthcare reform (4)
• HIV (1)
• immunotherapy (4)
• IND (2)
• Investigational New Drug Application (3)
• IPO (4)
• License (2)
• M&A (6)
• multidrug resistance (1)
• mutation (1)
• National Institutes of Health (1)
• NDA (3)
• neurology (3)
• neuroprostheses (1)
• neuroprosthetic (1)
• New Drug Application (7)
• Obesity (1)
• OIG (1)
• Orphan disease (7)
• pandemic (1)
• partnering (1)
• patent cliff (2)
• Patents (4)
• PDUFA (4)
• Personalized medicine (4)
• Pharmaceutical (21)
• Phase I (5)
• Phase II (4)
• Phase III (6)
• Pipeline (6)
• Preclinical (2)
• prostate cancer (1)
• Rare disease (3)
• Reimbursement (9)
• REMS (1)
• RNAi (2)
• SEC (1)
• sequestration (1)
• Series A (1)
• Shareholder value (1)
• siRNA (2)
• Stem cell (2)
• Supplemental new drug application (2)
• TB (1)
• traumatic brain injury (1)
• Tuberculosis (2)
• Type 2 Diabetes (1)
• Uncategorized (14)
• Vaccine (4)
• venture captial (7)
• Video (5)
• virus (2)